Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced that it has entered into a five-year term loan facility with funds managed by Pharmakon Advisors, LP.

The non-dilutive financing consists of:

• $75 million tranche funded at closing, a portion of which was used to retire Kestra’s existing $45 million term loan and pay fees and expenses.
• $25 million tranche available at Kestra’s option through July 2027.
• $50 million tranche available at Kestra’s option through June 2028, subject to generating $150 million of trailing 12-months revenue.
• $50 million uncommitted tranche available for acquisitions at Kestra’s option, subject to Pharmakon’s consent.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.